NATERA ($NTRA) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.56 per share, missing estimates of -$0.55 by $0.01. The company also reported revenue of $696,640,000, beating estimates of $629,459,217 by $67,180,783.
Stock price change since market close: -3.28%
You can see Quiver Quantitative's $NTRA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NATERA Insider Trading Activity
NATERA insiders have traded $NTRA stock on the open market 219 times in the past 6 months. Of those trades, 0 have been purchases and 219 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 23 sales selling 194,077 shares for an estimated $44,699,425.
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 28 sales selling 207,708 shares for an estimated $39,925,592.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 21 sales selling 79,769 shares for an estimated $18,738,853.
- ROELOF BOTHA has made 0 purchases and 11 sales selling 75,000 shares for an estimated $17,708,935.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 34 sales selling 53,495 shares for an estimated $12,122,271.
- HERM ROSENMAN has made 0 purchases and 4 sales selling 48,419 shares for an estimated $11,011,477.
- JONATHAN SHEENA has made 0 purchases and 58 sales selling 44,619 shares for an estimated $9,702,947.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 19 sales selling 43,626 shares for an estimated $9,535,071.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 10 sales selling 26,137 shares for an estimated $6,047,654.
- ROY D. BAYNES has made 0 purchases and 8 sales selling 12,780 shares for an estimated $2,809,688.
- ROWAN E CHAPMAN has made 0 purchases and 3 sales selling 4,488 shares for an estimated $1,084,737.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
NATERA Hedge Fund Activity
We have seen 391 institutional investors add shares of NATERA stock to their portfolio, and 358 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COATUE MANAGEMENT LLC added 2,463,008 shares (+1446.1%) to their portfolio in Q4 2025, for an estimated $564,250,502
- WELLINGTON MANAGEMENT GROUP LLP added 2,420,263 shares (+94.7%) to their portfolio in Q4 2025, for an estimated $554,458,050
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,307,662 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $528,662,287
- JPMORGAN CHASE & CO added 1,225,420 shares (+10.5%) to their portfolio in Q4 2025, for an estimated $280,731,467
- RTW INVESTMENTS, LP removed 1,093,645 shares (-42.2%) from their portfolio in Q4 2025, for an estimated $250,543,133
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,075,426 shares (-9.0%) from their portfolio in Q4 2025, for an estimated $246,369,342
- CITADEL ADVISORS LLC removed 786,720 shares (-87.7%) from their portfolio in Q4 2025, for an estimated $180,229,684
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
NATERA Government Contracts
We have seen $463,800 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $154,100
- GENETIC TESTING: $79,200
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NATERA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 04/14/2026
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
- BTIG issued a "Buy" rating on 12/05/2025
- JP Morgan issued a "Overweight" rating on 11/25/2025
- UBS issued a "Buy" rating on 11/18/2025
- Stephens & Co. issued a "Overweight" rating on 11/13/2025
- Piper Sandler issued a "Overweight" rating on 11/11/2025
To track analyst ratings and price targets for NATERA, check out Quiver Quantitative's $NTRA forecast page.
NATERA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 13 analysts offer price targets for $NTRA in the last 6 months, with a median target of $260.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $250.0 on 03/03/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $260.0 on 02/27/2026
- Brandon Couillard from Wells Fargo set a target price of $215.0 on 02/27/2026
- Catherine Ramsey from Baird set a target price of $257.0 on 02/27/2026
- Patrick Donnelly from Citigroup set a target price of $300.0 on 01/07/2026
- Subbu Nambi from Guggenheim set a target price of $270.0 on 01/05/2026
- Kyle Mikson from Canaccord Genuity set a target price of $285.0 on 12/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
